Table 2. ORs and corresponding 95% CIs for NHL by presence of hepatitis virus markers (Swiss HIV Cohort Study, 1984–2004).
|
NHL cases
|
Control subjects
|
||||
|---|---|---|---|---|---|
| Seropositivity | N | (%) | N | (%) | OR (95% CI)a |
| Anti-HCV | |||||
| No | 198 | (66.4) | 605 | (68.1) | 1b |
| Yes | 100 | (33.6) | 284 | (32.0) | 1.05 (0.63–1.75) |
| Anti-HBc | |||||
| No | 101 | (34.0) | 305 | (34.4) | 1b |
| Yes | 196 | (66.0) | 581 | (65.6) | 0.85 (0.61–1.18) |
| HBsAg | |||||
| No | 279 | (95.6) | 790 | (93.7) | 1b |
| Yes | 13 | (4.5) | 53 | (6.3) | 0.62 (0.32–1.20) |
Anti-HCV=antibodies against hepatitis C virus; anti-HBc=antibodies against hepatitis B core antigen; HBsAg=antibodies against hepatitis B surface antigen; NHL=non-Hodgkin's lymphoma; OR=odds ratios; CI=confidence intervals.
a
Estimated from conditional logistic regression analysis, conditioned on centre, gender, age group, and CD4+ count at enrolment and adjusted for HIV-transmission category and year of enrolment.
b
Reference category.